welcome to DuchenneXchange- a positively charged Duchenne muscular dystrophy community.
- join today!
- log in
The Validation Process for Confirmation of the French Version of the Pediatric Quality of Life Inventory (PedsQLTM)
study id #: NCT03513367
condition: Duchenne Muscular Dystrophy
There isn’t specific Health related quality of life measure for children with DMD in French. The aim of this study is to validate the French version of the Pediatric Quality of Life Inventory 3.0 Duchenne Muscular Dystrophy module with a multicentric study. The investigators will evaluate the following psychometric properties : convergent validity, internal validity, inter-rater reliability. The investigators would like to be able to use this scientific tool in future clinical trials.
Duchenne Muscular Dystrophy of the PedsQL ™ 3.0 scale,
The following data of motor function
mechanism of action: No pharmaceutical intervention
last updated: February 25, 2020
start date: September 19, 2018
estimated completion: September 19, 2019
phase of development: N/A
size / enrollment: 210
The Duchenne Muscular Dystrophy, the commonest form of dystrophy, is an X-linked, recessive neuromuscular disease, in which there is an absence of the protein dystrophin. This chronic and progressive disease leads to an inevitable loss of autonomy (muscle weakness, respiratory and cardiac failure). With better multidisciplinary care, life expectancy has increased but also morbidity. From now one, the evaluation of the quality of life of children with DMD is necessary in therapeutic trials.
Given the specificities of the disease, it seems appropriate to have a specific scale. In the literature there isn't quality of life scale specific to Duchenne Muscular Dystrophy in French version. The only specific scale that exists is the specific module PedsQLTM DMD that was validated in English version in 2012. This scale is relevant for assessing the quality of life in clinical trials and in daily clinical practice given its psychometric properties (good internal consistency close to 0.8).The main hypothesis that we formulate is to validate the French translation of the pediatric module of Duchenne Muscular Dystrophy of the PedsQL ™ 3.0 scale.
- Evaluate the validity of the French version of the DMD module of the PedsQLTM 3.0 scale [Time Frame: 12 months]
The validation process is confirmatory, the scale being widely used in English 201/5000 The internal consistency of the 4 dimensions of the PedsQL ™ DMD module will be evaluated by measuring the Cronbach Alpha. In terms of data availability to children (activity report), the validation of the DMD module will focus on the validity of constructs, internal structure validity, discriminant validity and reliability
- Evaluate the reliability of the French version of the DMD module of the PedsQLTM 3.0 scale [Time Frame: 12 months]
- PedsQLTM is a model for measuring quality of life in children with acute or chronic pathology. Pathology-specific PedsQL ™ provides a better assessment of the quality of life of this population
• Eligible Sexes: male
• Boys aged 7 to 18, with genomic Duchenne muscular dystrophy whose parents (mother and/or father) or direct grandparents do not oppose.
• Inability for the child to understand the issues
• Absence of direct parents or grandparents
• Child receiving antidepressant treatment
• Non French speaking child
• Duchenne Muscular Dystrophy girls
Living with Muscular Dystrophy: Blake’s Worldhttps://www.youtube.com/watch?v=p6ygJ6lA...
Clinical Trial to Evaluate the Efficacy, Safety, and Tolerability of RO7239361 in Ambulatory Boys With Duchenne Musc...This is a multi-center, randomized, doub...
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Dose of SRP-5051 in Patients With Duc...The purpose of this study is to evaluate...
zachsbattleZachary is 6 and has Duchenne Muscular D...
Teachers Resource: Duchenne muscular dystrophy (DMD)Duchenne muscular dystrophy affects appr...
Rare diseases require unique approaches in clinical trial designThere are 7,000 known rare diseases and ...
Extension Study of ACE-031 in Subjects With Duchenne Muscular DystrophyTo evaluate the long-term safety and tol...
Andy Turns 34 and He Battles Duchenne Muscular Dystrophy!https://www.youtube.com/watch?v=_id8zkvf...